Which statement best describes the function of low molecular weight heparin (LMWH) during pregnancy?

Low molecular weight heparin (LMWH) plays a crucial role in preventing thrombosis-related complications during pregnancy, making the statement about its function in this context the most accurate. During pregnancy, hormonal changes and increased pressure on venous circulation can elevate the risk of thrombosis, such as deep vein thrombosis (DVT) or pulmonary embolism (PE). LMWH works by inhibiting specific clotting factors, thereby reducing the likelihood of clot formation and enhancing blood flow.

The management of gestational diabetes is not associated with LMWH; instead, it typically involves dietary changes, monitoring blood glucose levels, and sometimes the use of insulin or oral medications. LMWH does not influence fetal movement; fetal activity is primarily determined by other factors such as fetal health and gestational age. Additionally, the safety of LMWH is not restricted only to the third trimester; it has established safety and efficacy across the entire pregnancy duration for certain high-risk patients, particularly those with a history of thromboembolic events. Hence, its preventive function against thrombosis-related complications is vital for minimizing risks during this period.